Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The advent of immune checkpoint inhibition for the treatment of patients with primary advanced or recurrent dMMR/MSI high endometrial cancer in 2025.

Current opinion in obstetrics & gynecology - 1 Feb 2025

Silk Tarik, Hacker Kari E, Growdon Whitfield, Pothuri Bhavana

Abstract excerpt

PURPOSE OF REVIEW: The Cancer Genome Atlas identified four distinct molecular subtypes of endometrial cancer (EC): POLE mutated, mismatch repair deficient (dMMR), copy number low, and copy number high. The goal of this review is to summarize the profound clinical implications of molecular subtyping, particularly in guiding treatment decisions for dMMR and microsatellite instability high (MSI-H) EC. RECENT...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Mismatch Repair
Share to DNA Polymerase II

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endometrial Neoplasms

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Microsatellite Instability

Share to Neoplasm Recurrence, Local

Share to Poly-ADP-Ribose Binding Proteins

Source

Identifiers

PMID: 39611619
DOI: 10.1097/GCO.0000000000001004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The advent of immune checkpoint inhibition for the treatment of patients with primary advanced or recurrent dMMR/MSI high endometrial cancer in 2025.PMID 39611619Read ↗

Traditional and New Views on MSI-H/dMMR Endometrial Cancer.Semantic proximity Read ↗

A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instabilitySemantic proximity Read ↗

Tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study.Semantic proximity Read ↗

A tale of two pathways: Review of immune checkpoint inhibitors in DNA mismatch repair‐deficient and microsatellite instability‐high endometrial cancersSemantic proximity Read ↗

Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial CarcinomaSemantic proximity Read ↗

Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune MicroenvironmentSemantic proximity Read ↗

New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere.Semantic proximity Read ↗

Molecular subtypes of endometrial cancer: Implications for adjuvant treatment strategies.Semantic proximity Read ↗

Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer.Semantic proximity Read ↗

Molecular testing for endometrial cancer: An SGO clinical practice statement.Semantic proximity Read ↗

Real-world prevalence of microsatellite instability testing and related status in women with advanced endometrial cancer in EuropeSemantic proximity Read ↗

High-plex spatial transcriptomic profiling reveals distinct immune components and the HLA class I/DNMT3A/CD8 modulatory axis in mismatch repair-deficient endometrial cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.